Renal outcomes in CVOTs: keep calm and carry on

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 9, 2018, Pages 674-676

  Muskiet, Marcel H A ^a   van Baar, Michaël J B ^a   Scholtes, Rosalie A ^a   van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN;

CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; KIDNEY;

CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY;

EID: 85048928314     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30195-5     Document Type: Note

References (12)

1. US Department of Health and Human Services, US Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic thearpies to treat type 2 diabetes. December https://www.fda.gov/downloads/Drugs/Guidances/ucm071627.pdf, 2008. (Accessed 1 June 2018)
2. Cefalu, WT, Kaul, S, Gerstein, HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care editors' expert forum. Diabetes Care 41 (2018), 14–31.
3. Holman, RR, Sourij, H, Califf, RM, Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017.
4. Muskiet, MHA, Tonneijck, L, Smits, MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13 (2017), 605–628.
5. van Bommel, EJ, Muskiet, MH, Tonneijck, L, Kramer, MH, Nieuwdorp, M, van Raalte, DH, SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome. Clin J Am Soc Nephrol 12 (2017), 700–710.
6. Perkovic, V, de Zeeuw, D, Mahaffey, KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol, 2018 published online June 21. http://dx.doi.org/10.1016/S2213-8587(18)30141-4.
7. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
8. Neal, B, Perkovic, V, Mahaffey, KW, et al. Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials. Diabetes Obes Metab 19 (2017), 926–935.
9. Neal, B, Perkovic, V, Mahaffey, KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
10. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
11. Cherney, DZI, Zinman, B, Inzucchi, SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
12. Wanner, C, Inzucchi, SE, Zinman, B, Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 1801–1802.